Detalhe da pesquisa
1.
Pathogen-focused Clinical Development to Address Unmet Medical Need: Cefiderocol Targeting Carbapenem Resistance.
Clin Infect Dis
; 69(Suppl 7): S559-S564, 2019 11 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-31724048
2.
Compassionate Use of Cefiderocol as Adjunctive Treatment of Native Aortic Valve Endocarditis Due to Extremely Drug-resistant Pseudomonas aeruginosa.
Clin Infect Dis
; 68(11): 1932-1934, 2019 05 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-30418554
3.
A phase 3 randomized controlled trial of a COVID-19 recombinant vaccine S-268019-b versus ChAdOx1 nCoV-19 in Japanese adults.
Sci Rep
; 14(1): 9830, 2024 04 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38684712
4.
A SARS-CoV-2 recombinant spike protein vaccine (S-268019-b) for COVID-19 prevention during the Omicron-dominant period: A phase 3, randomised, placebo-controlled clinical trial.
Vaccine
; 42(17): 3699-3709, 2024 Jun 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38734495
5.
Safety and immunogenicity of a booster dose of S-268019-b: Interim findings of a Phase 3, open-label clinical study in Japan.
Vaccine X
; 15: 100390, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37822891
6.
Results from a preclinical study in rodents and a Phase 1/2, randomized, double-blind, placebo-controlled, parallel-group study of COVID-19 vaccine S-268019-a in Japanese adults.
Vaccine
; 41(11): 1834-1847, 2023 03 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36572603
7.
Phase 1/2 clinical trial of COVID-19 vaccine in Japanese participants: A report of interim findings.
Vaccine
; 40(27): 3721-3726, 2022 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35606235
8.
Immunogenicity and safety of booster dose of S-268019-b or BNT162b2 in Japanese participants: An interim report of phase 2/3, randomized, observer-blinded, noninferiority study.
Vaccine
; 40(32): 4328-4333, 2022 07 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35738968
9.
Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial.
Lancet Infect Dis
; 21(2): 213-225, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33058798
10.
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
Lancet Infect Dis
; 21(2): 226-240, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33058795
11.
Designing A Pathogen-Focused Study To Address The High Unmet Medical Need Represented By Carbapenem-Resistant Gram-Negative Pathogens - The International, Multicenter, Randomized, Open-Label, Phase 3 CREDIBLE-CR Study.
Infect Drug Resist
; 12: 3607-3623, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31819544
12.
Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.
Lancet Infect Dis
; 18(12): 1319-1328, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30509675
13.
Prevalence of Carbapenem-Resistant Gram-Negative Infections in the United States Predominated by Acinetobacter baumannii and Pseudomonas aeruginosa.
Open Forum Infect Dis
; 4(3): ofx176, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-29026867
14.
Criteria for safety evaluation of antimicrobial agents.
J Infect Chemother
; 17(1): 139-47, 2011 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-21207093